AIM vs. OSTX, SRZN, CVKD, CLNN, ELEV, IRD, IBIO, SNYR, COEP, and PLUR
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include OS Therapies (OSTX), Surrozen (SRZN), Cadrenal Therapeutics (CVKD), Clene (CLNN), Elevation Oncology (ELEV), Opus Genetics (IRD), iBio (IBIO), Synergy CHC Corp. (Uplisting) (SNYR), Coeptis Therapeutics (COEP), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry.
AIM ImmunoTech vs.
OS Therapies (NYSE:OSTX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
AIM ImmunoTech received 52 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 83.10% of users gave AIM ImmunoTech an outperform vote.
OS Therapies has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. OS Therapies' return on equity of 0.00% beat AIM ImmunoTech's return on equity.
In the previous week, AIM ImmunoTech had 5 more articles in the media than OS Therapies. MarketBeat recorded 7 mentions for AIM ImmunoTech and 2 mentions for OS Therapies. AIM ImmunoTech's average media sentiment score of 0.59 beat OS Therapies' score of 0.06 indicating that AIM ImmunoTech is being referred to more favorably in the news media.
12.0% of AIM ImmunoTech shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
OS Therapies has higher earnings, but lower revenue than AIM ImmunoTech.
OS Therapies currently has a consensus target price of $17.50, indicating a potential upside of 1,115.28%. AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 2,189.76%. Given AIM ImmunoTech's higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than OS Therapies.
Summary
AIM ImmunoTech beats OS Therapies on 8 of the 14 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
This page (NYSE:AIM) was last updated on 3/3/2025 by MarketBeat.com Staff
Free AIM Stock Alerts